iCAD, Inc. (NASDAQ:ICAD) Short Interest Down 14.5% in January

iCAD, Inc. (NASDAQ:ICAD) was the target of a large decrease in short interest in the month of January. As of January 15th, there was short interest totalling 215,000 shares, a decrease of 14.5% from the December 31st total of 251,500 shares. Based on an average trading volume of 268,000 shares, the short-interest ratio is currently 0.8 days. Currently, 0.9% of the shares of the stock are sold short.

iCAD Stock Up 1.0 %

Shares of iCAD stock traded up $0.03 during trading on Friday, reaching $3.17. The company’s stock had a trading volume of 918,369 shares, compared to its average volume of 664,845. iCAD has a 52-week low of $1.18 and a 52-week high of $3.78. The company has a market cap of $84.13 million, a price-to-earnings ratio of -24.35 and a beta of 1.40. The firm’s 50-day moving average is $1.96 and its two-hundred day moving average is $1.72.

Institutional Investors Weigh In On iCAD

A number of institutional investors have recently made changes to their positions in the business. Essex LLC bought a new stake in shares of iCAD in the 3rd quarter worth approximately $216,000. waypoint wealth counsel lifted its stake in iCAD by 44.0% in the fourth quarter. waypoint wealth counsel now owns 14,400 shares of the technology company’s stock worth $26,000 after acquiring an additional 4,400 shares during the period. Finally, Summit Trail Advisors LLC bought a new stake in iCAD in the fourth quarter valued at $214,000. Hedge funds and other institutional investors own 24.61% of the company’s stock.

Analyst Ratings Changes

Separately, StockNews.com lowered shares of iCAD from a “hold” rating to a “sell” rating in a report on Friday.

About iCAD

iCAD, Inc engages in the provision of cancer detection and therapy solutions in the United States. It operates through two segments, Detection and Therapy. The company provides ProFound AI for digital breast tomosynthesis and 2D mammography; PowerLook, a density assessment solution; and ProFound Risk, a breast cancer risk analysis.